Democratizing Risk Stratification: In-Silico Validation and Pharmacoeconomic Assessment of SLC2A1 as a Low-Cost Prognostic Biomarker for Cervical Cancer
JCO Global Oncology · 01.11.2026 · 12 (Supplement_1) · 169-169
DOI: 10.1200/go-26-12800 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, erschienen am 01.11.2026. Verfasst von Fernando Augusto Siuta dos Santos und 9 weiteren Autor:innen.
Abstract (Originalsprache)
PURPOSE High-cost prognostic genomic panels exacerbate health disparities, particularly for cervical cancer in low- and middle-income countries (LMICs). This study validates the transcriptomic prognostic power of the hypoxia biomarker SLC2A1 (GLUT1), evaluating the clinical and economic viability of utilizing highly affordable immunohistochemistry (IHC) to democratize precision risk stratification in resource-constrained public health systems. METHODS A retrospective in-silico survival and pharmacoeconomic analysis was performed using the Kaplan-Meier Plotter RNA-seq database for cervical squamous cell carcinoma (CESC). Patients were stratified by SLC2A1 mRNA expression. Prognostic impact was quantified via overall survival (OS), log-rank testing, and hazard ratios (HRs). An economic impact model compared the utility of a proposed sub-$30 US dollars (USD) IHC proxy test against standard $3,000 USD comprehensive genomic profiling. RESULTS Analysis of the CESC cohort (N = 304) established high SLC2A1 expression as a critical, independent predictor of mortality. Stratification yielded n = 80 high-expression and n = 224 low-expression patients. The high-expression cohort experienced a drastically accelerated mortality rate, characterized by an HR of 1.87 (95% CI, 1.16 to 3.04). This translates to an 87% increased risk of death ( P = .0097). Clinically, this biomarker predicted a severe median OS reduction of 14.3 months, with the high-expression group surviving a median of 21.2 months versus 35.5 months for the low-expression group. Pharmacoeconomic modeling demonstrates that substituting $3,000 USD genomic panels with a $30 USD single-marker IHC assay achieves highly significant prognostic stratification while representing a 99% cost reduction, saving public health systems approximately $2,970 USD per patient stratified. CONCLUSION SLC2A1 overexpression is a robust, quantifiable predictor of severe mortality in cervical cancer. Translating this transcriptomic data into a low-cost IHC clinical assay offers a 99% cost-saving alternative to broad genomic panels. Prioritizing single-biomarker validation is a high-yield pharmacoeconomic strategy to bridge the precision oncology gap and optimize resource allocation in LMICs.
Zitieren
APA
Santos, F. A. S. D., Marin, P. D., Scain, G., Fink, I. A., Cé, J. L. C., Brum, S. K., Weber, M. W., Sá, M. D., Girardi, R. S., & Melo, S. D. (2026). Democratizing Risk Stratification: In-Silico Validation and Pharmacoeconomic Assessment of SLC2A1 as a Low-Cost Prognostic Biomarker for Cervical Cancer. JCO Global Oncology, 12(Supplement_1), 169-169. https://doi.org/10.1200/go-26-12800
Vancouver
Santos FASD, Marin PD, Scain G, Fink IA, Cé JLC, Brum SK, et al. Democratizing Risk Stratification: In-Silico Validation and Pharmacoeconomic Assessment of SLC2A1 as a Low-Cost Prognostic Biomarker for Cervical Cancer. JCO Global Oncology. 2026;12(Supplement_1):169-169. doi:10.1200/go-26-12800
BibTeX
@article{Santos2026,
author = {Santos, Fernando Augusto Siuta dos and Marin, Pedro Dytz and Scain, Giulia and Fink, Isabela Alicia and Cé, Julia Loureiro Chaves and Brum, Stéphanie Klein and Weber, Mariana Weremeier and Sá, Martina de and Girardi, Rafaela Sumienski and Melo, Solana de},
title = {Democratizing Risk Stratification: In-Silico Validation and Pharmacoeconomic Assessment of SLC2A1 as a Low-Cost Prognostic Biomarker for Cervical Cancer},
journal = {JCO Global Oncology},
year = {2026},
volume = {12},
number = {Supplement_1},
pages = {169--169},
doi = {10.1200/go-26-12800}
}
EUVIMED